Trade-Related Court Cases Filed for Week of March 5-11

The following lawsuits were filed at the Court of International Trade during the week of March 5-11:

Acetris Health, challenging CBP's final determination that its rosuvastatin calcium tablets, formulated and processed in the U.S. using an active ingredient from India and other ingredients from elsewhere, are not U.S. origin for government procurement purposes. #18-00040. Filed March 7.

Acetris Health, challenging CBP's final determination that its levofloxacin tablets, formulated and processed in the U.S. using an active ingredient from India and other ingredients from elsewhere, are not U.S. origin for government procurement purposes. #18-00041. Filed March 7.

Acetris Health, challenging CBP's final determination that its levetiracetam tablets, formulated and processed in the U.S. using an active ingredient from India and other ingredients from elsewhere, are not U.S. origin for government procurement purposes. #18-00042. Filed March 7.

Acetris Health, challenging CBP's final determination that its metoprolol tartrate tablets, formulated and processed in the U.S. using an active ingredient from India and other ingredients from elsewhere, are not U.S. origin for government procurement purposes. #18-00043. Filed March 7.

Acetris Health, challenging CBP's final determination that its gabapentin capsules, formulated and processed in the U.S. using an active ingredient from India and other ingredients from elsewhere, are not U.S. origin for government procurement purposes. #18-00044. Filed March 7.

Acetris Health, challenging CBP's final determination that its carvedilol tablets, formulated and processed in the U.S. using an active ingredient from India and other ingredients from elsewhere, are not U.S. origin for government procurement purposes. #18-00045. Filed March 7.

Acetris Health, challenging CBP's final determination that its paroxetine hydrochloride tablets, formulated and processed in the U.S. using an active ingredient from India and other ingredients from elsewhere, are not U.S. origin for government procurement purposes. #18-00046. Filed March 7.

Acetris Health, challenging CBP's final determination that its entecavir tablets, formulated and processed in the U.S. using an active ingredient from India and other ingredients from elsewhere, are not U.S. origin for government procurement purposes. #18-00047. Filed March 7.

Acetris Health, challenging CBP's final determination that its montelukast sodium tablets, formulated and processed in the U.S. using an active ingredient from India and other ingredients from elsewhere, are not U.S. origin for government procurement purposes. #18-00048. Filed March 7.

Acetris Health, challenging CBP's final determination that its simvastatin tablets, formulated and processed in the U.S. using an active ingredient from India and other ingredients from elsewhere, are not U.S. origin for government procurement purposes. #18-00049. Filed March 7.

Acetris Health, challenging CBP's final determination that its donepezil hydrochloride tablets, formulated and processed in the U.S. using an active ingredient from India and other ingredients from elsewhere, are not U.S. origin for government procurement purposes. #18-00050. Filed March 7.

Bio-Lab, Inc., Clearon Corp., and Occidental Chemical Corporation, challenging the Commerce Department's final results of its antidumping duty administrative review on chlorinated isocyanurates from China covering entries in 2015-16. #18-00051. Filed March 7.

​Appeals of CIT Decisions

No appeals of Court of International Trade decisions were filed at the U.S. Court of Appeals for the Federal Circuit during the week of March 5-11.